Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis [see comments] NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis [see comments]

AIDS. 1992 Aug;6(8):827-30. Unique Identifier : AIDSLINE MED/93039867
Pachon J; Cisneros JM; Castillo JR; Garcia-Pesquera F; Canas E; Viciana P; Infectious Diseases Unit, Hospital Universitario Virgen del; Rocio, Sevilla, Spain.

Abstract: OBJECTIVE: To study the pharmacokinetics of zidovudine (ZDV) and its glucoronide metabolite (G-ZDV) in a patient with end-stage renal disease in haemodialysis. DESIGN: Pharmacokinetics study performed during and between haemodialysis sessions. METHODS: The patient was treated with oral ZDV (100 mg every 8 h). Concentrations of ZDV and G-ZDV were measured by radioimmunoassay. A monocompartmental model was used to calculate pharmacokinetic parameters. RESULTS: The peak plasma concentrations of ZDV and G-ZDV after drug administration between haemodialysis sessions were 0.57 and 10.01 micrograms/ml, respectively. The half-lives of ZDV and G-ZDV rose to 3.2 and 14.2 h, respectively. The total body clearance for ZDV in the period between haemodialysis sessions (0.44 l/kg/h) was 66% lower than normal values. The ZDV half-life was normalized by haemodialysis, the total body clearance of ZDV increased (1.12 l/kg/h) and the G-ZDV half-life shortened (5.9-7.9 h). Neither G-ZDV accumulation nor derived ZDV toxicity occurred. CONCLUSIONS: Our data suggest that ZDV is safe and an efficient drug when administered at a dosage of 100 mg three times daily in patients with end-stage renal disease in haemodialysis sessions, and that ZDV and G-ZDV are cleared by haemodialysis.
Keywords: Case Report *Hemodialysis Human HIV Infections/*COMPLICATIONS/DRUG THERAPY Kidney Failure, Chronic/COMPLICATIONS/*METABOLISM Male Middle Age Zidovudine/*PHARMACOKINETICS/THERAPEUTIC USE JOURNAL ARTICLEKWDcasereportKWDhemodialysishumanhivinfections/KWDcomplications/drugtherapykidneyfailure,chronic/complications/KWDmetabolismmalemiddleagezidovudine/KWDpharmacokinetics/therapeuticusejournalarticle
Comment in: AIDS 1993 Jan;7(1):141-2
930228
M9320827

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .